Search Results - Conor C Lynch

  • Showing 1 - 8 results of 8
Refine Results
  1. 1

    Emerging roles for stromal cells in bone metastasis by Karl J. Nyman, Jeremy S. Frieling, Conor C. Lynch

    Published in Journal of Bone Oncology (2024-08-01)
    Get full text
    Article


  2. 2

    Integrated computational and in vivo models reveal Key Insights into macrophage behavior during bone healing. by Etienne Baratchart, Chen Hao Lo, Conor C Lynch, David Basanta

    Published in PLoS Computational Biology (2022-05-01)
    Get full text
    Article


  3. 3

    An osteoblast-derived proteinase controls tumor cell survival via TGF-beta activation in the bone microenvironment. by Sophie Thiolloy, James R Edwards, Barbara Fingleton, Daniel B Rifkin, Lynn M Matrisian, Conor C Lynch

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  4. 4

    An MMP13-selective inhibitor delays primary tumor growth and the onset of tumor-associated osteolytic lesions in experimental models of breast cancer. by Manisha Shah, Dexing Huang, Tony Blick, Andrea Connor, Lawrence A Reiter, Joel R Hardink, Conor C Lynch, Mark Waltham, Erik W Thompson

    Published in PLoS ONE (2012-01-01)
    Get full text
    Article


  5. 5

    EphA2 Is a Clinically Relevant Target for Breast Cancer Bone Metastatic Disease by David B Vaught, Alyssa R Merkel, Conor C Lynch, James Edwards, Mohammed Noor Tantawy, Timothy Hilliard, Shan Wang, Todd Peterson, Rachelle W Johnson, Julie A Sterling, Dana Brantley‐Sieders

    Published in JBMR Plus (2021-04-01)
    Get full text
    Article


  6. 6

    The bone ecosystem facilitates multiple myeloma relapse and the evolution of heterogeneous drug resistant disease by Ryan T. Bishop, Anna K. Miller, Matthew Froid, Niveditha Nerlakanti, Tao Li, Jeremy S. Frieling, Mostafa M. Nasr, Karl J. Nyman, Praneeth R. Sudalagunta, Rafael R. Canevarolo, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch, David Basanta

    Published in Nature Communications (2024-03-01)
    Get full text
    Article


  7. 7

    Acid ceramidase controls proteasome inhibitor resistance and is a novel therapeutic target for the treatment of relapsed / refractory multiple myeloma by Ryan T. Bishop, Tao Li, Praneeth Sudalagunta, Mostafa Nasr, Karl J. Nyman, Raghunandan R. Alugubelli, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Bin Fang, Steven Grant, John Koomen, Ariosto S. Silva, Kenneth H. Shain, Conor C. Lynch

    Published in Haematologica (2024-12-01)
    Get full text
    Article


  8. 8

    #1. Acid ceramidase (ASAH1) is a key mediator of drug resistance in relapsed/refractory multiple myeloma by Ryan T. Bishop, Tao Li, Raghunandan R. Alugubelli, Mostafa Nasr, Karl J. Nyman, Praneeth Sudalagunta, Mark Meads, Jeremy Frieling, Niveditha Nerlakanti, Marilena Tauro, Oliver Hampton, Bin Fang, Steven Grant, John Koomen, Ariosto Siqueira Silva, Kenneth H. Shain, Conor C. Lynch

    Published in Journal of Bone Oncology (2024-04-01)
    Get full text
    Article


Search Tools: